FOXD2-AS1

Summary

FOXD2-AS1 (FOXD2 adjacent opposite strand RNA 1, HGNC:44256) is a long non-coding RNA gene on chromosome 1p33.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:44256
Approved symbol	FOXD2-AS1
Name	FOXD2 adjacent opposite strand RNA 1
Location	1p33
Locus type	RNA, long non-coding
Status	Approved
Aliases	MGC12982
Ensembl gene	ENSG00000237424
Ensembl biotype	lncRNA
Entrez	84793
RNAcentral	URS000075AEF0 — lncRNA, 2527 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000445551

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000445551 — 1 exons

Exon	Start	End
ENSE00001599258	47432133	47434641

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 87.18.

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	87.18	gold quality
upper arm skin	UBERON:0004263	84.06	gold quality
descending thoracic aorta	UBERON:0002345	78.33	gold quality
popliteal artery	UBERON:0002250	78.22	gold quality
tibial artery	UBERON:0007610	78.20	gold quality
sural nerve	UBERON:0015488	78.08	gold quality
aorta	UBERON:0000947	77.46	gold quality
thoracic aorta	UBERON:0001515	76.79	gold quality
ascending aorta	UBERON:0001496	76.70	gold quality
tibial nerve	UBERON:0001323	76.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.42	gold quality
right coronary artery	UBERON:0001625	74.18	gold quality
stromal cell of endometrium	CL:0002255	73.07	gold quality
left coronary artery	UBERON:0001626	72.85	gold quality
transverse colon	UBERON:0001157	72.66	gold quality
pancreatic ductal cell	CL:0002079	72.43	silver quality
cardiac muscle of right atrium	UBERON:0003379	71.89	gold quality
left ventricle myocardium	UBERON:0006566	71.76	gold quality
granulocyte	CL:0000094	71.65	gold quality
coronary artery	UBERON:0001621	71.64	gold quality
rectum	UBERON:0001052	71.15	gold quality
endocervix	UBERON:0000458	70.12	gold quality
colonic epithelium	UBERON:0000397	69.36	silver quality
tendon of biceps brachii	UBERON:0008188	69.18	gold quality
myocardium	UBERON:0002349	66.97	gold quality
right lobe of liver	UBERON:0001114	66.57	gold quality
mucosa of stomach	UBERON:0001199	65.07	gold quality
blood	UBERON:0000178	64.69	gold quality
nasal cavity epithelium	UBERON:0005384	64.65	gold quality
leukocyte	CL:0000738	63.84	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.74

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• These results suggest that lncRNA FOXD2-AS1 might act as a novel therapeutic target for NSCLC treatment. (PMID:28132805)
• FOXD2-AS1 promoted the progression of colorectal cancer by regulating EMT and Notch signaling pathway. (PMID:28925486)
• Results revealed that FOXD2-AS1 was up-regulated in nasopharyngeal carcinoma (NPC) tissues and that its overexpression is associated with poor prognosis. Its knockdown exerted tumor-suppressive roles via repressing NPC cell proliferation in vitro and tumor growth in vivo. FOXD2-AS1-mediated oncogenic functions were partly through its regulatory function of miR-363-5p and its target S100A1. (PMID:29248577)
• our findings revealed that FOXD2-AS1 was overexpressed in ESCC cancer tissues and predicted poor overall and disease free prognosis of ESCC patients. (PMID:29286915)
• The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1. (PMID:29445134)
• FOXD2-AS1 knock-down inhibited the tumor growth of bladder cancer cells. (PMID:29674277)
• FOXD2-AS1 was found to interact with microRNA (miR)-185-5p to modulate proliferation, migration, and invasion of colorectal cancer cells (PMID:29737580)
• FOXD2-AS1 acted as a tumor inducer in GC partly through EphB3 inhibition by direct interaction with EZH2 and LSD1. (PMID:29789713)
• FOXD2-AS1 could promote the growth of chondrocytes by targeting miR-206/CCND1 axis. (PMID:30119190)
• FOXD2AS1 was found to be overexpressed in hepatocellular carcinoma (HCC) tissues which resulted in significantly shortened patient survival. Its overexpression enhanced the viability and metastasis of HCC cells in vitro and in vivo. mechanistic studies revealed that FOXD2AS1 upregulated the expression of the miR206 target gene ANXA2 by acting as a miR206 sponge. (PMID:30272362)
• FOXD2-AS1 is associated with clinical progression in cutaneous melanoma patients, and functions as oncogenic lncRNA in cutaneous melanoma cells. (PMID:30426532)
• Overexpression of CCND2 suppressed FOXD2-AS1 knockdown-induced inhibition of glioma malignancy. Taken together, our findings highlight the FOXD2-AS1/miR-185-5p/CCND2 axis in the glioma development (PMID:30520141)
• CREB1-induced FOXD2-AS1 contributed to glioma progression by upregulating AKT1 via competitively binding to miR-185. (PMID:30553445)
• The abnormal upregulation of long noncoding RNA FOXD2 adjacent opposite strand RNA1 (FOXD2AS1) predicts poor prognosis in patients with Breast cancer (BC). Downregulation of FOXD2AS1 decreases cell proliferation, and migratory and invasive abilities in BC cells, and decreases the growth of transplanted tumors in vivo. (PMID:30628646)
• we summarized and figured out recent studies about the expression and molecular biological mechanisms of FOXD2-AS1 in tumor progression[review] (PMID:30723052)
• our study demonstrated that EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/beta-catenin signaling pathway. (PMID:30929558)
• FOXD2-AS1 could play a crucial role in the progression of OA, at least partially, by regulating miR-27a-3p/TLR4 axis (PMID:30945573)
• The FOXD2-AS1 could epigenetically silence CDKN1B by recruiting EZH2 to CDKN1B promoter region. (PMID:31004581)
• The results of the present study suggested that decreased FOXD2AS1 expression may inhibit the growth, migration and invasion of tumor cells, and it may regulate downstream gene expression. In conclusion, these findings indicated that FOXD2AS1 may be used as a potential therapeutic target and early tumor marker for the diagnosis and prognosis of osteosarcoma (OS). (PMID:31115575)
• FOXD2-AS1 is corelated with clinicopathological parameter of laryngeal squamous cell carcinoma and promotes cancer cell proliferation through targeting miR-206. (PMID:31163553)
• FOXD2-AS1, induced by transcription factor HIF-1alpha, acts as an oncogene in the osteosarcoma tumorigenesis and FOXD2-AS1 interacts with EZH2 to silence p21 protein. (PMID:31228799)
• Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway. (PMID:31347720)
• Elevated FOXD2-AS1 expression was associated with poor survival in patients with solid tumors and may serve as a potential prognostic biomarker for a variety of cancers (PMID:31378453)
• Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis. (PMID:31770107)
• LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1. (PMID:31841177)
• Long noncoding RNA FOXD2-AS1 promoted hepatocellular carcinoma development by regulation miR-185/AKT axis. (PMID:31841454)
• Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation. (PMID:31959918)
• LncRNA FOXD2-AS1 stimulates glioma progression through inhibiting P53. (PMID:32373975)
• Upregulation of long non-coding RNA FOXD2-AS1 promotes progression and predicts poor prognosis in tongue squamous cell carcinoma. (PMID:32531865)
• Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis. (PMID:32558350)
• FOXD2-AS1 promotes migration and invasion of head and neck squamous cell carcinoma and predicts poor prognosis. (PMID:32762453)
• Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation of MLH1. (PMID:32917950)
• Activation of LncRNA FOXD2-AS1 by H3K27 acetylation regulates VEGF-A expression by sponging miR-205-5p in recurrent pterygium. (PMID:33098266)
• Dysregulation of FOXD2-AS1 promotes cell proliferation and migration and predicts poor prognosis in oral squamous cell carcinoma: a study based on TCGA data. (PMID:33318296)
• Long Non-coding RNA FOXD2-AS1 Promotes Proliferation, Migration, and Invasion in Cholangiocarcinoma Through Regulating miR-760/E2F3 Axis. (PMID:33570683)
• LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression. (PMID:33577022)
• LncRNA FOXD2-AS1 promotes cell proliferation and invasion of fibroblast-like synoviocytes by regulation of miR-331-3p/PIAS3 pathway in rheumatoid arthritis. (PMID:34030529)
• Moderate Prognostic Value of lncRNA FOXD2-AS1 in Gastric Cancer with Helicobacter pylori Infection. (PMID:34478035)
• Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation. (PMID:34739394)
• Long Noncoding RNA FOXD2-AS1 Promotes Pancreas Adenocarcinoma Cell Invasion and Migration by Sponging miR-30a-3p to Upregulate COX-2. (PMID:35377978)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.